Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial
Hamer, Melinda J, Houser, Katherine V, Hofstetter, Amelia R, Ortega-Villa, Ana M, Lee, Christine, Preston, Anne, Augustine, Brooke, Andrews, Charla, Yamshchikov, Galina V, Hickman, Somia, Schech, Steven, Hutter, Jack N, Scott, Paul T, Waterman, Paige E, Amare, Mihret F, Kioko, Victoria, Storme, Casey, Modjarrad, Kayvon, McCauley, Melanie D, Robb, Merlin L, Gaudinski, Martin R, Gordon, Ingelise J, Holman, LaSonji A, Widge, Alicia T, Strom, Larisa, Happe, Myra, Cox, Josephine H, Vazquez, Sandra, Stanley, Daphne A, Murray, Tamar, Dulan, Caitlyn N M, Hunegnaw, Ruth, Narpala, Sandeep R, Swanson, Phillip A, Basappa, Manjula, Thillainathan, Jagada, Padilla, Marcelino, Flach, Britta, O’Connell, Sarah, Trofymenko, Olga, Morgan, Patricia, Coates, Emily E, Gall, Jason G, McDermott, Adrian B, Koup, Richard A, Mascola, John R, Ploquin, Aurélie, Sullivan, Nancy J, Ake, Julie A, Ledgerwood, Julie E, Lampley, Rebecca, Larkin, Brenda, Costner, Pamela, Wilson, Hope, Read, Mike
Published in The Lancet (British edition) (28.01.2023)
Published in The Lancet (British edition) (28.01.2023)
Get full text
Journal Article